Research Guide

Unlike traditional radiotherapy, which employs X-rays or gamma rays, proton beams exhibit a unique energy deposition pattern in matter. They deliver a lower dose as they enter the body and release most of their energy at a specific depth, known as the Bragg Peak. This Bragg Peak effect allows proton therapy to precisely concentrate a higher radiation dose on the tumor while minimizing damage to surrounding healthy tissues, achieving targeted "precision bombing" to cancer cell

The field of diabetes cell and gene therapy exhibits a development landscape where the United States and China possess distinct advantages: 1. The United States maintains leadership in original technology. 2. China holds advantages in the speed of clinical translation and patient resources. 3. International cooperation and complementarity are key for the future.

Hematopoietic Stem Cell Transplantation (HSCT) is an effective treatment for malignant hematological tumors. One of the key factors determining the success of HSCT is Human Leukocyte Antigen (HLA) matching. If the HLA of the donor and the patient (recipient) do not match, severe rejection may occur, even endangering life.

Thalassemia is an inherited hemolytic anemia caused by globin gene defects. First discovered along the Mediterranean coast, it derives its name from this region. Its core characteristic is impaired hemoglobin (Hb) synthesis due to globin gene mutations, leading to ineffective erythropoiesis and ultimately chronic anemia of varying severity.

Over the past six years, China’s minimally invasive cardiovascular surgery has achieved a leap from concept popularization to system restructuring at an astonishing pace: technological boundaries are expanding, regional gaps are narrowing, and the disciplinary structure is rebalancing. This is a quiet yet profound revolution, a transformation reshaping the fates of patients nationwide.

On January 27, 1964, Academician Lu Daopei, the "founder of bone marrow transplantation in China," successfully performed Asia's first and the world's fourth allogeneic bone marrow transplantation at Peking University People's Hospital. This opened the era of hematopoietic stem cell transplantation (HSCT) for treating hematological diseases in China, bringing new hope to countless hematology patients.

Zhou Zhou from Guangxi is a patient with severe β-thalassemia. After 16 years of blood transfusion, she and her family decided to undergo hematopoietic stem cell transplantation (HSCT). In 2021, the soon-to-be 17-year-old Zhou Zhou found the team led by Director Liao Jianyun. After two years of continuous iron chelation therapy, she underwent HSCT at Southern Chunfu (Children's) Institute of Hematology, Gobroad Medical (Hematology) Guangdong Research Center in 2023.

Team of Academician Wang Jian'an from the Second Affiliated Hospital of Zhejiang University Successfully Performed Two Transcatheter Edge-to-Edge Mitral Valve Repair Surgeries at the National Medical Research Center for Cardiology of the Russian Federation

Two weeks ago, 67-year-old Ms. Chen visited our department and was diagnosed with breast cancer after examination. After a comprehensive assessment of the patient's condition, Chief Physician Yang Mei decided to perform a robot-assisted breast cancer resection.

The procedure was performed percutaneously under DSA and ICE guidance. Post-procedure ultrasound confirmed the bioabsorbable PFO occluder had good morphology and position, complete closure with no residual shunt, no pericardial effusion, and no adverse reactions before or after closure, indicating successful closure.

In pursuit of proton therapy, Mr. C came to Guangzhou Concord Cancer Center . During examinations, abnormal thickening of his rectal wall was also discovered. Further colonoscopy and pathology results ultimately confirmed he had a second primary cancer: a rectosigmoid junction tumor.

One month ago, Ms. Li began experiencing symptoms including numbness on the left side of her face, veering to the left while walking, and occasional choking while eating. The progression of the disease caused Ms. Li significant anxiety, leading her to return to the Neurosurgery Department at Beijing Tiantan Puhua Hospital.

Ms. Zhu never imagined that at the age of 84, she would undergo such a "record-breaking" surgery. Doctors removed her entire pancreas, spleen, and gallbladder, reconstructed her gastrointestinal tract and blood vessels, and simultaneously performed an autologous islet transplantation.

CyberKnife is the world's first automated robotic radiosurgery system, perfectly embodying Stereotactic Body Radiotherapy (SBRT) principles. It delivers high-precision, personalized treatment solutions suitable for most solid tumors throughout the body.

Orlando, USA, Dec 6-9, 2025 – The 67th American Society of Hematology (ASH) Annual Meeting, one of the most influential global hematology events, convened top scholars and clinical experts from over 100 countries. The meeting served as a premier platform for exchanging groundbreaking research, diagnostic and treatment concepts, and practical experience, collectively shaping the future of hematology.

CyberKnife is the world's first automated robotic radiosurgery system, perfectly embodying Stereotactic Body Radiotherapy (SBRT) principles. It delivers high-precision, personalized treatment solutions suitable for most solid tumors throughout the body.

A Belgian MS patient, Alex, regained his life after CAR-T therapy in China - from wheelchair-bound to walking and embracing his child again. Huazhong University's Professor Wang Wei team pioneered the breakthrough, proving CAR-T can safely cross the blood-brain barrier to clear pathogenic B cells in CNS. Published in Cell, this marks a milestone in autoimmune disease treatment.

CAR-T therapy, the 4th major cancer treatment, engineers patient's T cells to target cancers. Highly effective for blood cancers like leukemia & lymphoma. Promising for solid tumors & non-cancer diseases. Faces challenges like cost & side effects, but research is advancing rapidly.

Lu Daopei Hospital's dual-target CAR-T saves critically ill international DLBCL patient! A 60-year-old Egyptian with massive abdominal tumor & TP53 mutations achieved remarkable recovery after CD19/CD22 CAR-T + radiotherapy. From unable to sit to walking out smiling.

Recently, the international hematology journal Blood Advances published a prospective clinical study by Lu Daopei Medical Team, titled "Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma," reporting breakthrough clinical results of BCMA-targeted nanobody-based CAR-T cell therapy in heavily pretreated refractory/relapsed plasma cell neoplasms.